Cagrilintide-semaglutide plus basal insulin lowered A1C and weight in adults with type 2 diabetes 24th September 20265th July 2026 by Living Diabetes Editorial A Lancet phase 3a trial found cagrilintide-semaglutide added to basal insulin lowered A1C and weight in adults with type 2 diabetes.
CagriSema for Weight Loss and Type 2 Diabetes: What to Know 24th September 20266th April 2026 by Living Diabetes Editorial Team CagriSema combines cagrilintide and semaglutide in trials. Learn what studies show, what remains uncertain, and safety caveats.
